Cargando…
AdipoRon prevents myostatin‐induced upregulation of fatty acid synthesis and downregulation of insulin activity in a mouse hepatocyte line
Liver diseases such as non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are characterized by excess hepatic accumulation of lipid droplets and triglycerides which are associated with defective insulin action. Myostatin (Mstn) and adiponectin, secreted by muscle cell...
Autores principales: | Liu, Xin‐Hua, Pan, Jiang Ping, Bauman, William A., Cardozo, Christopher P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597868/ https://www.ncbi.nlm.nih.gov/pubmed/31250564 http://dx.doi.org/10.14814/phy2.14152 |
Ejemplares similares
-
AdipoRon may be benefit for atherosclerosis prevention
por: Esfahani, Maryam, et al.
Publicado: (2017) -
AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy
por: Abou‐Samra, Michel, et al.
Publicado: (2020) -
AdipoRon Engages Microglia to Antinociception through the AdipoR1/AMPK Pathway in SNI Mice
por: Fang, Qian, et al.
Publicado: (2023) -
AdipoRon and Other Adiponectin Receptor Agonists as Potential Candidates in Cancer Treatments
por: Nigro, Ersilia, et al.
Publicado: (2021) -
Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines
por: Ragone, Angela, et al.
Publicado: (2022)